Medicamen Biotec (MEDICAMEQ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Low leverage with Debt/Equity of 0.14
• Piotroski F-Score of 7/9 indicates sound financial health signals
• P/B of 1.58 against Book Value of ₹164.34 offers some asset backing
• Price is well below the 52-week high of ₹447.65, reducing speculative froth
• Promoter holding of 40.46% provides reasonable alignment

Concerns

• P/E of 46.21 and PEG of 10.89 price in excessive expectations despite low growth
• ROE of 4.01% and ROCE of 6.77% show weak capital efficiency
• Sales growth of 5.71% and profit growth of 2.78% are subdued
• Dividend yield of 0.33% offers negligible income protection

AI Analysis

At ₹259, Medicamen Biotec is no compounder. Mr Market prices it at 46 times earnings, but the business has grown sales only 5.71% and profits 2.78%. That gives a PEG of 10.89—whatever growth exists is already more than paid for. Graham would ask: what am I getting? Book value ₹164 gives P/B 1.58, not extreme, but return on that book is just 4.01%; ROCE is 6.77%. A business earning 4% on equity is not creating much value for shareholders, especially after inflation. The balance sheet is reasonable—D/E 0.14, and Piotroski F-Score 7/9 hints at decent financial health. But a low-debt, mediocre-return pharma company is not a wonderful business at a fair price; it is a fair business at a demanding price. The latest quarter, ₹43 Cr sales and ₹3 Cr profit, confirms small scale. With promoter holding at 40.46%, I need to see whether they are buyers or sellers. Dividend yield of 0.33% means income seekers need not apply. The 52-week range of ₹216 to ₹447.65 shows the shares have fallen hard; Mr Market has soured. That is good—it creates a potential entry if fundamentals improve. But I do not just buy falling prices; I buy value. At 46 times earnings and single-digit growth, there is no margin of safety. If the business matures and growth stays below 5%, the earnings yield of roughly 2.2% cannot justify the risk. For an Indian retail investor, patience is key. Watch whether sales and profit growth accelerate, whether ROE climbs towards 12-15%, and whether the company uses its low debt to expand profitably. Until then, this goes on the watchlist, not the shopping list.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer